ALEXION PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult Volunteers
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT05396742
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH
Phase 3
Active, not recruiting
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- First Posted Date
- 2022-05-25
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT05389449
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05346354
- Locations
- 🇪🇸
Research Site, Esplugues de Llobregat, Spain
A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT05319912
- Locations
- 🇺🇸
Clinical Trial Site, Lincoln, Nebraska, United States
A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT05319899
- Locations
- 🇺🇸
Clinical Trial Site, Lincoln, Nebraska, United States
Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT05314231
- Locations
- 🇰🇷
Clinical Trial Site 2, Anyang-Si, Gyeonggi-do, Korea, Republic of
🇰🇷Clinical Trial Site 1, Seoul, Korea, Republic of
Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1910 in Healthy Participants
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05307978
- Locations
- 🇬🇧
Clinical Trial Site, Harrow, United Kingdom
Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05303324
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
A Study of Single and Multiple Doses of ALXN1210 in Healthy, Adult Japanese Participants
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT05288816
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
A Study of a Single Dose of ALXN1210 in Healthy Participants
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT05288660
- Locations
- 🇨🇦
Clinical Trial Site, Montréal, Canada